奥法妥木单抗治疗视神经脊髓炎谱系疾病合并干燥综合征1例报告OA

To investigate the potential therapeutic value of ofatumumab(OFA)in patients with neuromyelitis optica spectrum disorder(NMOSD)comorbid with Sjögren syndrome(SS).A retrospective analysis was performed for the clini-cal data of a patient who was admitted to our hospital on September 21,2022 and was diagnosed with NMOSD and SS,in-cluding clinical manifestations,imaging findings,and laboratory results.Under the premise of fully informed consent,the patient received OFA for B-cell depletion therapy to prevent disease recurrence.Disease conditions and adverse events were closely monitored throughout the treatment period.After more than three years of continuous treatment,although the patient developed a pulmonary space-occupying lesion,it did not progress to a malignant disease,and rabies vaccination following a dog bite did not trigger the disease activity of NMOSD or SS.No severe infection was observed during treat-ment,with satisfactory disease control and a significant improvement in quality of life.This case suggests that OFA may have favorable clinical efficacy and tolerability in patients comorbid with NMOSD and SS,thereby providing a new option for the treatment of such comorbidity.It should be noted that this regimen represents an off-label use,and prospective studies with a large sample size are needed to further validate its efficacy and safety.